Full-Time

Senior Data Management Engineer

Confirmed live in the last 24 hours

Calico Labs

Calico Labs

201-500 employees

Research and develop treatments for aging

Compensation Overview

$173k - $180k/yr

+ Annual Cash Bonuses

Senior

San Bruno, CA, USA

Hybrid

Must be willing to work onsite at least 4 days a week.

Category
Data Management
Data & Analytics
Required Skills
Python
SQL
Data Analysis
Requirements
  • 3+ years’ experience curating (organizing, cleaning, and efficiently manipulating) scientific datasets
  • Advanced knowledge of biology (degree in life sciences or computational biology, and/or experience working in a biology lab environment)
  • Detail-oriented with strong organizational, project management and analytical skills
  • Ability to work effectively with scientists and engineers to elucidate and translate data organization needs into written requirements and specifications
  • Ability to understand scientific literature, experimental procedures and their limitations, and current needs of the research community
  • Knowledge of SQL; familiarity with relational databases, relational data concepts and data modeling
  • Ability to clearly and concisely communicate technical, scientific and non-technical information, both verbally and in writing
  • Experience writing shell scripts and/or Python – including basic data extraction, transformation, loading, and analysis scripts
  • Must be willing to work onsite at least 4 days a week
Responsibilities
  • Work with scientists and engineers to identify optimal ways to prepare, annotate, store and navigate their datasets, including pairing with engineers on data application design and improvement
  • Define and document best practices for capturing and entering experimental metadata, and educate scientists and collaborators about these standards
  • Perform data wrangling tasks including cleaning, transforming, and labeling datasets and developing relevant schemas for storing that data
  • Maintain quality control and integrity of current and archived data
  • Build data models and processes based on business and technical requirements to channel data from multiple inputs through data pipelines, ensuring successful processing and data validity
Desired Qualifications
  • Familiarity with controlled vocabularies and ontologies
  • Advanced knowledge of bioinformatics, genomics, and proteomics methods
  • Advanced knowledge of data structures and formats used in scientific approaches
  • Experience assisting clinical personnel in data and metadata submission
  • Understanding of current regulatory guidelines, GCP, and industry standards, practices, and terminologies regarding data management
  • Ability to provide product specification and review as part of software development
  • Experience with Unix tools for data manipulation
  • Familiarity with software development processes in a collaborative setting, e.g. reading and reviewing teammates’ code in GitHub or similar source control
  • Experience interacting with information systems programmatically via a web API
  • Experience with data quality assessment
  • Applied Machine Learning experience for curation of historical / legacy lab data

Calico Labs focuses on researching the biology of aging and creating treatments for age-related diseases. The company conducts scientific research to understand how aging works and the diseases that come with it. By collaborating with academic institutions and other biopharmaceutical companies, Calico Labs combines advanced technologies with a culture of curiosity to drive innovation in this field. This partnership approach helps speed up research and increases the chances of making important discoveries. Calico Labs earns revenue through these collaborations, which often include joint research projects and shared intellectual property. The goal of Calico Labs is to significantly advance the understanding of aging and develop effective medical treatments for age-related conditions.

Company Size

201-500

Company Stage

Seed

Total Funding

$2M

Headquarters

South San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Calico's FDA START Pilot Program inclusion accelerates rare disease drug development.
  • Exclusive licensing with Mabwell enhances Calico's anti-aging therapeutic portfolio.
  • Michael Lenardo's appointment as CSO strengthens Calico's scientific leadership.

What critics are saying

  • Dependency on partnerships like AbbVie could impact Calico's R&D pipeline.
  • Ethical and regulatory challenges may hinder anti-aging research progress.
  • Increased competition from well-funded biotech companies like Altos Labs.

What makes Calico Labs unique

  • Calico Labs focuses on aging and age-related diseases, a niche in biopharmaceuticals.
  • The company leverages strategic partnerships, enhancing research and development capabilities.
  • Calico's collaboration with Broad Institute targets age-related neurodegeneration, extending until 2029.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Professional Development Budget

Company News

BioSpace
Jun 27th, 2025
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China's Mabwell

Alphabet's aging-focused subsidiary Calico Life Sciences has entered into an exclusive licensing agreement with Mabwell Bioscience to advance the Shanghai biotech's anti-IL-11 monoclonal antibodies for age-related diseases.

Fierce Biotech
Jun 26th, 2025
Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

According to the agreement, Calico will have exclusive rights to develop and commercialize 9MW3811 in all regions except greater China.

PR Newswire
Jun 7th, 2024
Calico Life Sciences Announces That Fosigotifator (Abbv-Cls-7262) For Vanishing White Matter Disease Has Been Selected For The Fda Start Pilot Program

SOUTH SAN FRANCISCO, Calif., June 7, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the U.S. Food and Drug Administration (FDA) Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. Fosigotifator is being developed by Calico and AbbVie pursuant to their 2014 collaboration as a potential treatment for Vanishing White Matter (VWM) disease.FDA's Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) initiated the START Pilot Program to help further accelerate the development of novel drug and biological products for rare diseases. Selected participants will be able to obtain frequent advice and enhanced communication with FDA review staff to address program-specific development issues, including, but not limited, to clinical study design, choice of control group, and fine-tuning the choice of patient population."Calico is honored that fosigotifator has been selected by CDER as one of three candidates for the FDA's innovative START Pilot Program. The inclusion of fosigotifator underscores the potential of this investigational therapy in addressing the unmet needs of individuals and families affected by Vanishing White Matter Disease," said Arthur D

PR Newswire
May 9th, 2024
Calico And Broad Institute Extend Collaboration Adding Focus On Age-Related Neurodegeneration

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico) and the Broad Institute of MIT and Harvard, announced today that the two organizations have further extended their partnership with an added focus on age-related neurodegeneration. Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed."We are pleased to continue our collaboration with the Broad Institute. It is entering its tenth year and we've made a considerable amount of progress, including discoveries that could make immunotherapies more effective for more patients. We are currently testing this approach in two early-stage clinical trials evaluating a pair of PTPN2 inhibitors," said Arthur D

PR Newswire
Mar 28th, 2024
Calico Appoints Michael Lenardo, M.D., As Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer. Dr. Lenardo will join the company in August after completing his term as Co-Director of the National Institute of Allergy and Infectious Diseases (NIAID) Clinical Genomics Program at the National Institutes of Health.Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades. He has been recognized for his work on fundamental immunological mechanisms and is particularly known for discovering the genetic basis, pathogenesis, and treatment of several congenital disorders of the immune system."Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr